Spravato Success Rate: What Clinical Studies Show
When you have already tried depression treatments, a headline about the Spravato success rate can bring both hope and skepticism. Research on Spravato effectiveness supports a benefit for some adults with treatment-resistant depression, including average symptom improvement in controlled trials and maintenance benefits among people who previously responded. It does not provide a guaranteed outcome for an individual patient.
To understand the evidence, look beyond one percentage. Ask who was studied, what treatment they received, what it was compared with, and whether the outcome was early improvement, remission, or avoiding a later relapse. Those are different questions.
How effective is Spravato? Define success before comparing results
Depression trials often use a clinician-rated scale such as the Montgomery–Åsberg Depression Rating Scale, or MADRS. A falling score indicates reduced measured symptom severity. A difference between average scores in two groups is not a percentage of people cured.
“Response” usually means a specified degree of improvement from baseline, often a reduction of at least half on the study's symptom scale. “Remission” means symptoms fall below a defined threshold. “Relapse” refers to a return of clinically important symptoms after improvement, according to the study's criteria.
The definitions and time points must stay attached to the results. Someone may improve without reaching remission, and someone in remission may still need ongoing care. A dramatic session experience is not one of these clinical outcomes.
Spravato clinical trials: what did the early add-on study show?
The TRANSFORM-2 randomized trial published in 2019 studied adults with treatment-resistant, nonpsychotic depression. It randomized 227 people; 197 completed the four-week treatment phase. One group received esketamine nasal spray and a newly started oral antidepressant. The comparison group received placebo nasal spray and a newly started oral antidepressant.
At day 28, the estimated average improvement in MADRS score favored the esketamine group by 4.0 points. The reported 95% confidence interval for the between-group difference was approximately 0.6 to 7.3 points in that direction. This describes an average additional effect under the study conditions, not a four-percent success rate.
Both groups received an active oral antidepressant. The trial therefore addressed the benefit of adding esketamine in that treatment setting; it did not compare Spravato directly with an intravenous ketamine course or TMS.
What does newer monotherapy research add?
A randomized monotherapy trial published in 2025 examined esketamine without an accompanying oral antidepressant in adults with treatment-resistant depression without psychotic features. Its main efficacy analysis included 378 participants who met the specified symptom-severity criteria and received study treatment.
After four weeks, the two esketamine dose groups showed average MADRS improvements that exceeded placebo by 5.1 and 6.8 points, respectively. The trial also found statistically significant differences at approximately 24 hours after the first treatment. These results concern group averages, not a promise that every patient will improve by the next day.
The study broadens the evidence beyond the older add-on design. It does not show that stopping an oral antidepressant improves outcomes, and patients should not reproduce the trial's medication changes themselves. Whether monotherapy is appropriate requires a prescribing decision.
What does the maintenance evidence show?
The SUSTAIN-1 randomized withdrawal study asked a different question: after people improved with esketamine plus an oral antidepressant, did continuing esketamine delay relapse? After an initial 16 weeks, 297 participants who achieved stable remission or response entered the randomized maintenance phase.
Among the 176 participants in the stable-remission group, relapse occurred in 24 of 90 people continuing esketamine plus an oral antidepressant, or 26.7%. It occurred in 39 of 86 switched to placebo nasal spray while continuing the oral antidepressant, or 45.3%, during the maintenance study.
These findings support continued-treatment benefit in selected people who had already improved. They do not tell a new patient their chance of responding at the start, and they are not fixed one-year relapse rates. The study's withdrawal design and follow-up conditions matter when interpreting the result.
Why there is no single universal Spravato success rate
A clinic may report a response rate, a study may report remission, and an advertisement may mention a reduction in relapse risk. Those figures cannot be substituted for one another. Even results with the same label can come from different patient groups and different follow-up periods.
Ask whether a quoted percentage includes everyone who started treatment or only those who completed a course. Ask how adverse effects, early discontinuation, and missing follow-up were handled. These questions help distinguish an encouraging number from a result that actually answers your concern.
The controlled trials above include researchers affiliated with the manufacturer. That does not automatically invalidate the findings, but affiliations and financial disclosures should be read alongside study methods and limitations. This article reviews selected trials rather than providing a complete systematic review of every study.
Who do these findings apply to most directly?
The strongest inference from a trial is about people resembling its participants receiving a similar intervention. The studies discussed here focused on adults with treatment-resistant depression; several specified depression without psychotic features. Their findings should not automatically be transferred to every age group, diagnosis, or severity level.
A personal assessment also considers medical risks, other medicines, previous responses, and practical access. There is no basis in these studies for claiming that one personality type, one symptom, or the intensity of dissociation reliably identifies who will do best.
Bring your own treatment history to a discussion of depression care. It can help a clinician explain how closely the research fits your situation and where uncertainty remains, rather than relying on a broad average.
Benefit must be weighed against safety and burden
The current Spravato prescribing information includes risks such as sedation, dissociation, respiratory depression, blood-pressure increases, and abuse or misuse. Treatment takes place under supervision with at least two hours of post-administration monitoring and an assessment before discharge.
Current labeling allows Spravato alone or with an oral antidepressant for adult TRD. The separate indication involving depressive symptoms with acute suicidal ideation or behavior uses an oral antidepressant alongside it. The label also states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated.
Study results do not remove the burden of transport, repeated appointments, cost, adverse effects, or follow-up. A benefit that is meaningful to one person may need to be weighed differently by another. Discuss the whole plan rather than evaluating medication in isolation.
Make the evidence useful in your own treatment plan
Before treatment, agree with your clinician on how symptoms and functioning will be assessed. Name specific difficulties: getting out of bed, preparing food, concentrating, connecting with others, or experiencing pleasure. These goals complement clinical measures rather than replace them.
During treatment, report adverse effects and changes in safety as well as positive changes. Do not feel obliged to describe an improvement because you have invested time or money. Honest follow-up helps determine whether to continue, change the wider plan, or consider another option.
For TRD, the label calls for assessment of benefit at the end of the initial four-week phase. Ask what the review will involve and how maintenance decisions will be made. Therapy and counseling or other appropriate care may remain part of the broader plan, depending on your needs.
Discussing the research with Sophroneo
Sophroneo Behavioral Health & TMS lists Spravato among its mental health services. With locations in Powder Springs and Marietta, the practice serves the Atlanta area.
Contact Sophroneo to discuss an assessment and bring questions about evidence, safety, access, and alternatives. A useful consultation connects the research to your history while making clear that no published study can guarantee your outcome.
Frequently asked questions
How long does Spravato take to work?
Some controlled trials detected group-level symptom differences at about 24 hours, but individual timing varies. An early change is not the same as full remission or a lasting response. Discuss expectations and follow-up with your clinician rather than judging treatment by a single day.
Do maintenance results mean I must stay on it forever?
No. The maintenance study supports continuation for selected prior responders under its conditions. It does not define a lifelong schedule for every patient. Duration and frequency need periodic clinical review based on benefit, risks, and individual circumstances.
Does a study percentage tell me my personal chance of recovery?
Not precisely. A result describes a particular population and outcome under specified conditions. Your clinician can explain its relevance to you, but should not present a trial average as an individualized guarantee.
This article is educational, not a personal treatment recommendation. In the United States, call or text 988 for emotional crisis support. Call 911 for immediate danger or a life-threatening emergency; a routine treatment appointment does not replace urgent care.
Comments